Cat. #161783
OV-3133(R2) cell line
Cat. #: 161783
Availability: 8-10 weeks
Organism: Human
Tissue: Derived from ascites of patient diagnosed with high-grade serous ovarian cancer at specific time points at diagnosis and relapse
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Anne-Marie Mes-Masson and Diane Provencher
Institute: Centre Hospitalier de Luniversité de Montréal
Primary Citation: Létourneau et al. 2012. BMC Cancer. (12): 379. PMID: 22931248
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: OV-3133(R2) cell line
- Alternate name: OV-3133(R2)
- Cancer: Gynaecologic cancer
- Research fields: Cancer
- Organism: Human
- Gender: Female
- Tissue: Derived from ascites of patient diagnosed with high-grade serous ovarian cancer at specific time points at diagnosis and relapse
- Donor: Grade 3 Stage IIIC; Mutations: TP53 Exon 6; Carboplatin/Taxol/Doxorubicin & Carboplatin/Gemcitabine/Doxorubicin
- Morphology: No expression of the tumor suppressor p53 detected. Strong HER2 expression detected in protein extracts and observed in solid tissues by IHC. Spheroid formation: aggregate
- Growth properties: Adherent
- Crispr: No
- Receptors of note: No
- Description: Epithelial ovarian cancer cell lines spontaneously derived from ascites of patient diagnosed with high-grade serous ovarian cancer at specific time points at diagnosis and relapse (R). Primary treatment included paclitaxel and carboplatin and later treatment included doxorubicin, carboplatin, gemcitabine, and etoposide.
- Production details: Established from the cellular fraction of ascites collected by centrifugation. The cell lines were then maintained for 40 days in OSE with medium replaced weekly.
- Additional notes: Patient 3133 received treatment of paclitaxel and carboplatin 1-3 months after sugery and confirmation of ovarian cancer diagnosis. A second sugery 6 months after the first detectede infiltration of the tumor in part of the abdomen. Patient was treated with dxorubicin and later carboplatin and gemcitabine after no significant changes of CA-125 levels were seen. Later imaging presented an increase in tumor mass whereby she was given etoposide orally for eight days.
Handling
- Growth medium: OSE medium contains 10% FBS, 0.5ug/mL amphotericin B and 50 ug/mL gentamicin
- Atmosphere: Hypoxic condition of 5%O2 and 5%CO2
- Cultured in antibiotics: Amphotericin B and Gentamicin
References
- Tomas et al. 2023. J Ovarian Res. 11
- 16(1):70. PMID: 37038202 Vias et al. 2023. Elife. 11
- 12:e83867. PMID: 37166279 Jubelin et al. 2022. Cell Biosci. 11
- 12(1):155. PMID: 36089610 Canals et al. 2022. Front Oncol. 4
- 12:856424. PMID: 35600398
